Market Movers

Elevance Health, Inc.’s Stock Price Suffers a 2.76% Dip, Now Trading at $382.14: A Detailed Analysis

By December 7, 2024 No Comments

Elevance Health, Inc. (ELV)

382.14 USD -10.84 (-2.76%) Volume: 2.72M

Explore Elevance Health, Inc.’s stock price performance, currently standing at 382.14 USD, experiencing a decrease of -2.76% this trading session with a trading volume of 2.72M. Despite the challenging market conditions, Elevance Health has shown resilience, even with a year-to-date percentage change of -18.96%.


Latest developments on Elevance Health, Inc.

Elevance Health, Inc. (NYSE:ELV) stock has been experiencing fluctuations recently, hitting a 52-week low at $391.01. Shareholders have been closely monitoring the stock’s performance, with Quadrature Capital Ltd boosting their stake while HighTower Advisors LLC decided to sell shares. Stifel Financial Corp, Royal London Asset Management Ltd, and Erste Asset Management GmbH have also made moves in relation to their holdings in Elevance Health, Inc. Amidst these changes, investors are questioning if Elevance Health stock is underperforming the Dow. In other news, Anthem has reversed its decision to cap anesthesia coverage in Connecticut after facing backlash from doctors over the new time limits.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars